Indirect Comparison Between Eltrombopag & Romiplostim

GlaxoSmithKline1 enrolled

Overview

An indirect comparison to compare the efficacy of eltrombopag versus romiplostim

An indirect analysis was conducted to evaluate the relative efficacy of eltrombopag and romiplostim using placebo as a common comparator

Study Type

OBSERVATIONAL

Enrollment

Conditions

Thrombocytopaenia

Interventions

EltrombopagDRUG

Eltrombopag \& standard of care

RomiplostimDRUG

Romiplostim \& standard of care

PlaceboDRUG

Placebo \& standard of care

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults with ITP * Pre-specified treatment * Prospective clinical studies with at least 10 patients Exclusion Criteria: * Adults with ITP for other reasons

Outcomes

Primary Outcomes

Durable response: platelet count of >=50 and <400 Gi/L

Time frame: 6 months

Overall response: either a durable response or a transient platelet response

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.